TNRC18 and acute myeloid leukemia: However, the advancement and widespread use of next-generation sequencing technologies, mainly RNA-Seq, have opened up new possibilities to identify novel gene fusions as molecular biomarkers for disease monitoring and treatment optimization.15 In this study, we used targeted RNA-Seq to identify a rare NUP98::TNRC18 fusion in a patient with AML.